Fresenius SE & Co KGaA

Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.
  • TickerFRE
  • ISINDE0005785604
  • SectorHealth Care Equipment & Services
  • CountryGermany

Fresenius Se & Co Kgaa: 1 director bought

A director at Fresenius Se & Co Kgaa bought 3,000 shares at 38.848EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Expert Corporate Governance Service (ECGS)

Fresenius SE & Co. KGaA - AG% 28 Augusut 2020

General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company. Item 1: Unlike at German stock corporations, shareholders of a KGaA are legally required to vote on the annual accounts. We have no concerns and recommend shareholders to approve the Company's annual accounts. We have no concerns ov...

For FRESENIUS, the environment deterioration entails a downgrade to Neutral

FRESENIUS (DE), a company active in the Health Care Providers industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 4 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date July 10, 2020, the closing price was EUR 44.31 and its expected value was estimated at EUR 43.10.

Fresenius SE & Co. KGaA - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Fresenius SE & Co. KGaA: Update to credit analysis

Our credit view of Fresenius SE & Co. KGaA, reflecting its financial performance in 2019 and our updated expectations for the next 12-18 months.

Dave Nicoski ...
  • Ross LaDuke

Int'l Macro Vision: Sector Synopsis

Int'l Equity Strategy In using technical analysis, we let the market be our guide. That is, we analyze what is true in the market, utilizing the vast array of tools in our technical analysis toolbox which we then formulate into our outlook using a weight of the evidence approach. In a world where there are no shortages of things to worry about (trade wars, central banks, Trump impeachment, negative interest rates, low global growth, Brexit, Manufacturing weakness, elections, Hong Kong protests, the list goes on...), our tools help us cut through the noise and conjecture. After all, what if th...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad in the eyes of the market. While we view the fact that none of these issues have yet to derail global...

Jérôme VINERIER

Analyse court terme - FRESENIUS SE & CO KGAA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 55,10 €, puis 51,43 €. Le franchissement de 64,80 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - FRESENIUS SE & CO KGAA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €55.10, then €51.43. Passing €64.80 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - FRESENIUS SE & CO KGAA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 58,90 €, puis 55,10 €. Le franchissement de 70,90 € remettrait en cause la suite de la baisse.

Fresenius Se & Co Kgaa: 1 director bought

A director at Fresenius Se & Co Kgaa bought 3,000 shares at 38.848EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior